NetScientific is a life sciences and technology investment and commercialisation company. PDS Biotechnology (Nasdaq: PDSB) a portfolio company of NetScientific (5.75% undiluted holding) yesterday announced that it has achieved its preliminary objective response for the National Cancer Institute's (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment.
04 Feb 2021
WHI First Light: NetScientific (NSCI) - PDS Biotech announces preliminary efficacy achievement
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WHI First Light: NetScientific (NSCI) - PDS Biotech announces preliminary efficacy achievement
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
04 Feb 2021 -
Author:
John Cummins | Matthew Davis -
Pages:
4
NetScientific is a life sciences and technology investment and commercialisation company. PDS Biotechnology (Nasdaq: PDSB) a portfolio company of NetScientific (5.75% undiluted holding) yesterday announced that it has achieved its preliminary objective response for the National Cancer Institute's (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment.